ISOREA - News

ISOREA AB Secures €2.5 Million in Non-Dilutive Funding to Accelerate Alzheimer’s Blood Test Development

Mon, 26 Jan 2026 12:42:00 +0000

ISOREA AB is pleased to announce that it has been awarded approximately 25 million SEK (€2.5 million) in non-dilutive soft funding from the Bulgarian Ministry of Innovation and Growth, through its wholly owned subsidiary ISOREA Bulgaria EOOD. The funding was granted under the “Research, Innovation and Digitalisation for Smart Transformation” programme, following ISOREA’s Seal of Excellence from the EIC Accelerator.

This funding marks a significant milestone for ISOREA and will substantially accelerate the development and clinical validation of the company’s early Alzheimer’s disease risk detection blood test, while meaningfully reducing both technical and investment risk.

The achievement reflects the strong leadership and dedication of ISOREA’s CEO/VD, Dr. Sourav Prasanna Mukherjee, and COO, Dr. Sanchali Gupta, as well as the close and effective collaboration with ISOREA’s Bulgarian partner New-I, led by Mr. Anton Todorov and Ms. Zhechka Kalinova.

As part of this development, Dr. Sanchali Gupta has been appointed Managing Director of ISOREA Bulgaria EOOD by the ISOREA AB Board, led by Chairperson Prof. Roman Zubarev. She will oversee the execution of the funded project with the support of the broader ISOREA team.

With this funding secured, ISOREA is well positioned to advance its diagnostic programs toward market readiness. The company welcomes interest from investors seeking to participate in the next phase of ISOREA’s growth.

ISOREA has been Awarded the Eureka Eurostars Grant!

Mon, 24 Feb 2025 14:25:00 +0000

We are thrilled to announce that ISOREA AB, in collaboration with Karolinska Institutet and Davids Biotechnologie GmbH , has been awarded a prestigious Eureka Eurostars grant and the project will start from April 2025! This achievement represents a major step forward in our mission to revolutionise Alzheimer’s Disease detection by identifying the risks 6–10 years before noticeable symptoms develop and are possible to treat at this stage.

Eurostars is highly regarded for fostering collaborative and market-focused R&D initiatives, and we are privileged to join this dynamic community of innovators Eureka Network. This grant will accelerate our efforts in advancing research and expanding the application of our antibodies for early risk detection of Alzheimer’s Disease.

We extend our heartfelt thanks to our CEO, Sourav Pr. Mukherjee, Ph.D., for leading the consortium and coordinating this remarkable project, as well as to Professor Roman Zubarev from Karolinska Institutet and Dr. Michael Davids from Davids Biotechnologie for their invaluable contributions. Together, this collaborative effort has paved the way for this achievement. We are excited for the journey ahead, driven by innovation, teamwork, and impactful advancements.

Stay tuned as we dive into this exciting new chapter—we’re thrilled to share our journey and updates with you every step of the way!

ISOREA Received EIC Seal of Excellence!

Mon, 24 Feb 2025 14:08:00 +0000

ISOREA was awarded the European Innovation Council (EIC) Seal of Excellence for our EIC Accelerator application in July 2024. Although we were not granted funding due to EIC budget constraints. However, this prestigious recognition enhances our opportunities to secure funding and investments from alternative sources.

ISOREA AB received investment from Linnéa Capital AB

Thu, 20 Jul 2023 10:14:00 +0000

ISOREA AB is very happy to announce that we have received an investment from Linnéa Capital AB. This investment will help ISOREA AB to start its IVDR application procedure of the KIT designed to detect Early Alzheimer's by a sensitive and affordable blood test.

Our KIT has the potential to detect Alzheimer's disease at Early stage or Mild Cognitive Impairment (MCI) stage and thereby helping patients to start medical interventions using new age drugs developed by other providers for patients at MCI stage. This KIT is also vital for blood screening at the Blood Banks before transfusion to the recipients, as a preventative measure from receiving isoaspartate containing bad albumin.

ISOREA AB is now part of UIC Accelerator

Wed, 25 Jan 2023 10:00:00 +0000

We are glad to announce that ISOREA AB has been selected in the prestigious Uppsala Innovation Centre (UIC) Accelerator Program. This is one of the top 5 accelerator programs in the world. We are very happy to be a part of it and getting connected with its vast investor and professional network. Apart from receiving financial support from UIC, we will also receive various advice through their great mentorship program.

We look forward to our journey together!

Pic. Mrs. Helena Kristersson (Program Director UIC Accelerator; centre) and Mr. Vinh Hoang (UIC associate; right) visiting the laboratory of Professor Roman Zubarev (Chairperson & CSO, ISOREA AB) at Karolinska Institutet. They are received by Dr. Sourav Pr. Mukherjee (CEO ISOREA AB; left).

Fri, 14 Oct 2022 14:49:00 +0000